Aytu BioPharma enacts 1-for-20 reverse stock split to regain Nasdaq $1.00 bid compliance

AYTU BIOPHARMA, INC

1-for-20 reverse split reduces outstanding shares from ~68.8M to ~3.4M.
Company must maintain closing bid ≥$1.00 for 10 consecutive days by May 22, 2023 to comply with Nasdaq.
Proportional adjustments to warrants, options, and equity plan pool; no fractional shares—cash in lieu.
New CUSIP 054754858; shares continue trading under ticker AYTU on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

AYTU BIOPHARMA, INC: Approved a 1-for-20 reverse stock split via a Certificate of Amendment to the Certificate of Incorporation, effective January 6, 2023 (effective 2023-01-06).

Change: charter amendment
Effective: 2023-01-06

Exact text from the filing

On January 4, 2023, the Board of Directors of Aytu BioPharma, Inc. (“the Company” or “Aytu”) approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective at 12:01 a.m. Eastern Time on Friday, January 6, 2023 pursuant to a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Certificate of Incorporation.

View on SEC.gov

Browse all governance changes →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-001400

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.